Clinical Trials Logo

Astrocytoma of Brain clinical trials

View clinical trials related to Astrocytoma of Brain.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04091503 Completed - Gliosarcoma Clinical Trials

Evaluate the Safety and Effectiveness of Intranasal Administration of Temozolomide in Patients With Glioblastoma

Start date: December 20, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this pilot study is to determine the safety, tolerability, and the maximum tolerated dose intranasal administration of temozolomide (TMZ) as a single agent in Treatment on the patients with GBM. Intranasal administration is a new method of treating brain tumours for the direct administration of drugs, inhibitors or viruses, with minimal involvement of the BBB. The investigators know the orally prescribed standard chemotherapy temozolomide (TMZ) is widely used to treat glioma tumours. Received evidence of safety and efficacy in a full cycle of preclinical trials (on GLP Standart) and tests of calculated doses of intranasal administration of TMZ in healthy volunteers. Intranasal administration of temozolomide is considered as GBM therapy, which provides direct access to a therapeutic dose of the drug into the brain (to the neoplastic process) with low toxicity

NCT ID: NCT03020602 Completed - Glioblastoma Clinical Trials

BPM31510 in Treating Patients With Recurrent High-Grade Glioma Previously Treated With Bevacizumab

Start date: January 4, 2017
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of ubidecarenone injectable nanosuspension (BPM31510) in treating patients with high-grade glioma (anaplastic astrocytoma or glioblastoma) that has come back and have been previously treated with bevacizumab. BPM31510 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.